Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more
Coeptis Therapeutics Inc (COEP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.165x
Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) has a cash flow conversion efficiency ratio of -0.165x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.15 Million) by net assets ($13.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coeptis Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Coeptis Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coeptis Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Coconut Public Company Limited
BK:COCOCO
|
0.054x |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
0.077x |
|
Paxman AB
PINK:PXMBF
|
-0.014x |
|
Chino Commercial Bancorp
PINK:CCBC
|
0.006x |
|
VirTra Inc
NASDAQ:VTSI
|
0.001x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.131x |
|
PEDEVCO Corp
NYSE MKT:PED
|
0.064x |
|
Solytech Enterprise Corp
TW:1471
|
0.004x |
Annual Cash Flow Conversion Efficiency for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual cash flow conversion efficiency of Coeptis Therapeutics Inc from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.87 Million | $-6.65 Million | -1.719x | -97.56% |
| 2023-12-31 | $4.45 Million | $-3.88 Million | -0.870x | -7.86% |
| 2022-12-31 | $4.80 Million | $-3.88 Million | -0.807x | +57.75% |
| 2021-12-31 | $2.35 Million | $-4.49 Million | -1.910x | -413.23% |
| 2020-12-31 | $-5.14 Million | $-3.14 Million | 0.610x | +110.62% |
| 2019-12-31 | $15.69K | $-90.07K | -5.739x | +87.74% |
| 2018-12-31 | $17.93K | $-839.06K | -46.804x | -6291.45% |
| 2005-12-31 | $-551.66K | $-417.02K | 0.756x | +112.84% |
| 2004-12-31 | $-264.01K | $1.55 Million | -5.885x | -- |